Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.62 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12871351 | 0.87 | NPC1 (0.90) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL30416225 | 0.85 | NPC1 (0.70) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL16461033 | 0.85 | RAB9A (0.70) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL3850447 | 0.85 | NPC1 (0.70) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL6497202 | 0.84 | RAB9A (0.68) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL31325157 | 0.84 | RAB9A (0.68) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL29598340 | 0.84 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ACES2 | |
| Hydrochloric Acid SCHEMBL30102161 | 0.84 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL21779857 | 0.84 | RAB9A (0.68) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL4331173 | 0.84 | RAB9A (0.68) | NPC1RAB9AMEN1KMT2ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | claimed |
| EP-3624804-B1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | ANNJI PHARM CO LTD (TW) | 2022-02-16 | — | — | EP | claimed |
| EP-1517880-B1 | PRODUCTION OF CIS-PELLITORIN AND USE AS A FLAVOURING | SYMRISE AG (DE) | 2011-01-05 | — | — | EP | claimed |
| EP-1461010-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | Integriderm, Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030199558-A1 | Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners | INTEGRIDERM, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003057184-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | INTEGRIDERM, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-118724753-A | Method for promoting synthesis of hydroxamic acid by using metal salt | 沈阳药科大学 | 2024-10-01 | — | — | CN | disclosed |
| EP-4387603-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-116870016-B | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118103038-A | 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3197560-A1 | CAPSULE AGGREGATES | International Flavors & Fragrances Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016054351-A1 | CAPSULES CONTAINING POLYVINYL ALCOHOL | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016049456-A1 | CAPSULE AGGREGATES | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2013059582-A2 | SMALL MOLECULE INHIBITORS OF HISTONE DEACTEYLASES | NUPOTENTIAL, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| EP-1461010-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | Integriderm, Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003057184-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | INTEGRIDERM, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199558-A1 | Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners | TYR, MC1R, MITF | NPC1 4218/4885RAB9A 3599/4885SMPD1 4459/4885 |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | PSEN2, PSEN1, VHL | NPC1 643/4885RAB9A 1496/4885SMPD1 440/4885 |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | NPC1 472/4885RAB9A 3762/4885SMPD1 391/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | NPC1 472/4885RAB9A 3762/4885SMPD1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.